Pci Biotech Holding Stock Current Ratio

Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

In accordance with the recently published financial statements, PCI Biotech Holding has a Current Ratio of 16.24 times. This is much higher than that of the Biotechnology sector and 132.0% higher than that of the Health Care industry. The current ratio for all Norway stocks is notably lower than that of the firm.

The Macroaxis Fundamental Analysis modules help investors analyze PCI Biotech Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PCI Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PCI Biotech Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.